tradingkey.logo
tradingkey.logo
Suchen

Daxor Corp

DXR
Zur Watchlist hinzufügen
10.750USD
-0.510-4.51%
Handelsschluss 05/15, 16:00ETKurse um 15 Minuten verzögert
62.64MMarktkapitalisierung
30.92KGV TTM

mehr Informationen über Daxor Corp Unternehmen

Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.

Daxor Corp Informationen

BörsenkürzelDXR
Name des UnternehmensDaxor Corp
IPO-datumJul 25, 1983
CEOFeldschuh (Michael Richard)
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeJul 25
AddresseSuite 7120
StadtNEW YORK
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl10118
Telefon12122440555
Websitehttps://www.daxor.com/
BörsenkürzelDXR
IPO-datumJul 25, 1983
CEOFeldschuh (Michael Richard)

Führungskräfte von Daxor Corp

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael Richard Feldschuh
Mr. Michael Richard Feldschuh
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
213.69K
+0.47%
Mr. Jonathan Adam Feldschuh
Mr. Jonathan Adam Feldschuh
Chief Scientific Officer, Director
Chief Scientific Officer, Director
53.91K
+33.39%
Mr. Robert J. (Bob) Michel
Mr. Robert J. (Bob) Michel
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
21.05K
+4.75%
Mr. Edward Feuer, CPA
Mr. Edward Feuer, CPA
Independent Director
Independent Director
1.00K
--
Dr. Henry D. Cremisi, M.D.
Dr. Henry D. Cremisi, M.D.
Independent Director
Independent Director
--
--
Ms. Joy Goudie, Esq.
Ms. Joy Goudie, Esq.
Independent Director
Independent Director
--
--
Mr. Bret Shapiro
Mr. Bret Shapiro
IR Contact Officer
IR Contact Officer
--
--
Mr. Caleb Desrosiers, Esq.
Mr. Caleb Desrosiers, Esq.
Independent Director
Independent Director
--
--
Mr. John Jefferies
Mr. John Jefferies
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael Richard Feldschuh
Mr. Michael Richard Feldschuh
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
213.69K
+0.47%
Mr. Jonathan Adam Feldschuh
Mr. Jonathan Adam Feldschuh
Chief Scientific Officer, Director
Chief Scientific Officer, Director
53.91K
+33.39%
Mr. Robert J. (Bob) Michel
Mr. Robert J. (Bob) Michel
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
21.05K
+4.75%
Mr. Edward Feuer, CPA
Mr. Edward Feuer, CPA
Independent Director
Independent Director
1.00K
--
Dr. Henry D. Cremisi, M.D.
Dr. Henry D. Cremisi, M.D.
Independent Director
Independent Director
--
--
Ms. Joy Goudie, Esq.
Ms. Joy Goudie, Esq.
Independent Director
Independent Director
--
--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Sun, May 10
Aktualisiert: Sun, May 10
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Joseph Feldschuh UEO
43.82%
Feldschuh (Michael Richard)
3.67%
Feldschuh (Jonathan Adam)
0.93%
Vanguard Capital Management, LLC
0.83%
Renaissance Technologies LLC
0.48%
Andere
50.28%
Aktionäre
Aktionäre
Anteil
Joseph Feldschuh UEO
43.82%
Feldschuh (Michael Richard)
3.67%
Feldschuh (Jonathan Adam)
0.93%
Vanguard Capital Management, LLC
0.83%
Renaissance Technologies LLC
0.48%
Andere
50.28%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
49.03%
Investment Advisor
1.53%
Hedge Fund
0.48%
Research Firm
0.05%
Andere
48.90%

Institutionelle Beteiligung

Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
16
120.43K
2.07%
+11.27K
2025Q4
14
102.17K
2.33%
--
2025Q3
14
102.17K
2.33%
+2.08K
2025Q2
15
100.09K
2.26%
+3.04K
2025Q1
15
97.05K
2.30%
-16.23K
2024Q4
15
106.77K
1.91%
+12.72K
2024Q3
14
94.05K
1.85%
+4.76K
2024Q2
13
89.28K
1.77%
+4.12K
2024Q1
13
85.17K
1.54%
+11.30K
2023Q4
13
73.17K
1.98%
-131.00
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Joseph Feldschuh UEO
2.55M
43.82%
--
--
Dec 16, 2025
Feldschuh (Michael Richard)
212.69K
3.65%
--
--
Dec 16, 2025
Feldschuh (Jonathan Adam)
53.91K
0.93%
+18.00K
+50.13%
Dec 16, 2025
Renaissance Technologies LLC
28.22K
0.48%
-700.00
-2.42%
Dec 31, 2025
Michel (Robert J)
21.05K
0.36%
+1.00K
+4.99%
Mar 31, 2026
Jefferies (John M.D.)
10.93K
0.19%
+5.94K
+119.06%
Mar 20, 2026
Morgan Stanley Smith Barney LLC
3.24K
0.06%
-300.00
-8.48%
Dec 31, 2025
Mehr Anzeigen

Verbundene ETFs

Name
Anteil
Keine Daten

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI